Q-omics provides the consensus-scored NACAP6 profile across patient tissues and cancer cell-line models. NACAP6 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, NACAP6 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, NACAP6 RNA expression shows 5,427 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUSC as cancer lineages where NACAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACAP6 survival associations across molecular data types. NACAP6 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACAP6 RNA expression–survival associations across cancer types. High NACAP6 expression shows unfavorable associations in STAD, KIRP, THCA, BLCA, ACC and ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for NACAP6 RNA expression.
This table summarizes NACAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NACAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACAP6 shows higher tumor expression in LUSC. The LUSC box plot shows higher NACAP6 RNA expression in tumor versus normal tissue (log2 FC = +0.010, t-test p = .022).
This table shows molecular features associated with NACAP6 in patient tissues and cancer cell lines. In patient samples, NACAP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
